| 李建冰,李 杰,郭宏华,姜雪峰,黄丽珍.亮菌口服液改善慢性肝炎患者肝功能和肝纤维化的临床研究[J].,2023,(24):4678-4681 |
| 亮菌口服液改善慢性肝炎患者肝功能和肝纤维化的临床研究 |
| Clinical Study on Ameliorating Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis with Armillariella Oral Solution |
| 投稿时间：2023-05-24 修订日期：2023-06-21 |
| DOI：10.13241/j.cnki.pmb.2023.24.015 |
| 中文关键词: 亮菌口服液 慢性肝炎 临床疗效 肝功能 肝纤维化 不良反应 |
| 英文关键词: Armillaria oral solution Chronic hepatitis Clinical efficacy Liver function Liver fibrosis Adverse reaction |
| 基金项目:吉林省教育厅资助项目（JJKH20190067KJ） |
|
| 摘要点击次数: 270 |
| 全文下载次数: 139 |
| 中文摘要: |
| 摘要 目的：探讨亮菌口服液治疗慢性肝炎患者的临床疗效及对肝功能和肝纤维化的影响。方法：选取2018年6月~2021年1月吉林大学中日联谊医院收治的96例慢性肝炎患者作为研究对象，采用随机数字表法分为观察组和对照组各48例，对照组采用常规药物治疗，观察组在对照组的基础上加用亮菌口服液治疗。比较两组患者的临床疗效、肝功能、肝纤维化指标和不良反应情况。结果：观察组临床总有效率高于对照组（P＜0.05）；治疗后，观察组谷丙转氨酶（ALT）、谷草转氨酶（AST）、γ-谷氨酰转肽酶（γ-GT）明显低于对照组（P＜0.05）；治疗后，观察组患者透明质酸酶（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（Ⅳ-C）明显低于对照组（P＜0.05）；两组患者不良反应发生率比较无明显差异（P＞0.05）。结论：亮菌口服液治疗慢性肝炎患者效果显著，可明显改善患者的肝功能，减轻肝纤维化程度，且无显著不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of armillariella oral solution in treating patients with chronic hepatitis and its impact on liver function and liver fibrosis. Methods: A total of 96 patients with chronic hepatitis admitted to the Sino Japanese Friendship Hospital of Jilin University from June 2018 to January 2021 were selected as the study subjects. They were randomly divided into an observation group and a control group with 48 patients each. The control group was treated with conventional drugs, while the observation group was treated with armillariella oral solution on the basis of the control group. The clinical efficacy, liver function, liver fibrosis indicators, and adverse reactions of the two groups of patients were compared. Results: The total clinical effective rate in the observation group was higher than that in the control group(P<0.05); After treatment, the glutamic-pyruvic transaminase(ALT), glutamic-oxalacetic transaminase(AST), γ-glutamyl-transferase (γ-GT) in the observation group were significantly lower than that of the control group (P<0.05); After treatment, the hyaluronidase (HA), laminin (LN), type III procollagen (PC III) and type IV collagen (IV-C) in the observation group were significantly lower than those in the control group(P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The efficacy of armillariella oral solution in treating patients with chronic hepatitis is significant, it can significantly improve the liver function of patients, alleviate the degree of liver fibrosis, and has no significant adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
